MedPlus Health Services Limited
MedPlus Health Services Limited (MEDPLUS.BO) Stock Competitors & Peer Comparison
See (MEDPLUS.BO) competitors and their performances in Stock Market.
Peer Comparison Table: Medical - Pharmaceuticals Industry
Detailed financial metrics including price, market cap, P/E ratio, and more.
| Symbol | Price | Change % | Market Cap | P/E Ratio | EPS | Dividend Yield |
|---|---|---|---|---|---|---|
| MEDPLUS.BO | ₹835.45 | +0.00% | 102.8B | 49.65 | ₹17.26 | N/A |
| MEDPLUS.NS | ₹835.05 | +0.00% | 102.6B | 49.55 | ₹17.25 | N/A |
| GUJTHEM.BO | ₹318.80 | +0.00% | 34.3B | 71.75 | ₹4.39 | +0.21% |
| SHUKRAPHAR.BO | ₹37.45 | +0.00% | 17.1B | -195.35 | -₹0.20 | +0.05% |
| KPL.BO | ₹1,339.30 | +0.00% | 14.9B | 26.37 | ₹54.51 | N/A |
| SASTASUNDR.NS | ₹280.85 | +0.00% | 9B | 34.66 | ₹8.18 | N/A |
| SASTASUNDR.BO | ₹279.60 | +0.00% | 9B | 34.60 | ₹8.18 | N/A |
| FREDUN.BO | ₹1,646.60 | +0.00% | 7.8B | 23.53 | ₹69.98 | +0.04% |
| BPLPHARMA.BO | ₹1,095.00 | +0.00% | 7.7B | -26.16 | -₹42.81 | +0.09% |
| ANUHPHR.BO | ₹75.34 | +0.00% | 7.6B | 18.21 | ₹4.18 | +1.97% |
Stock Comparison
MEDPLUS.BO vs MEDPLUS.NS Comparison February 2026
MEDPLUS.BO plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, MEDPLUS.BO stands at 102.8B. In comparison, MEDPLUS.NS has a market cap of 102.6B. Regarding current trading prices, MEDPLUS.BO is priced at ₹835.45, while MEDPLUS.NS trades at ₹835.05.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
MEDPLUS.BO currently has a P/E ratio of 49.65, whereas MEDPLUS.NS's P/E ratio is 49.55. In terms of profitability, MEDPLUS.BO's ROE is +0.12%, compared to MEDPLUS.NS's ROE of +0.12%. Regarding short-term risk, MEDPLUS.BO is less volatile compared to MEDPLUS.NS. This indicates potentially lower risk in terms of short-term price fluctuations for MEDPLUS.BO.Check MEDPLUS.NS's competition here
MEDPLUS.BO vs GUJTHEM.BO Comparison February 2026
MEDPLUS.BO plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, MEDPLUS.BO stands at 102.8B. In comparison, GUJTHEM.BO has a market cap of 34.3B. Regarding current trading prices, MEDPLUS.BO is priced at ₹835.45, while GUJTHEM.BO trades at ₹318.80.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
MEDPLUS.BO currently has a P/E ratio of 49.65, whereas GUJTHEM.BO's P/E ratio is 71.75. In terms of profitability, MEDPLUS.BO's ROE is +0.12%, compared to GUJTHEM.BO's ROE of +0.19%. Regarding short-term risk, MEDPLUS.BO is less volatile compared to GUJTHEM.BO. This indicates potentially lower risk in terms of short-term price fluctuations for MEDPLUS.BO.Check GUJTHEM.BO's competition here
MEDPLUS.BO vs SHUKRAPHAR.BO Comparison February 2026
MEDPLUS.BO plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, MEDPLUS.BO stands at 102.8B. In comparison, SHUKRAPHAR.BO has a market cap of 17.1B. Regarding current trading prices, MEDPLUS.BO is priced at ₹835.45, while SHUKRAPHAR.BO trades at ₹37.45.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
MEDPLUS.BO currently has a P/E ratio of 49.65, whereas SHUKRAPHAR.BO's P/E ratio is -195.35. In terms of profitability, MEDPLUS.BO's ROE is +0.12%, compared to SHUKRAPHAR.BO's ROE of +0.47%. Regarding short-term risk, MEDPLUS.BO is less volatile compared to SHUKRAPHAR.BO. This indicates potentially lower risk in terms of short-term price fluctuations for MEDPLUS.BO.Check SHUKRAPHAR.BO's competition here
MEDPLUS.BO vs KPL.BO Comparison February 2026
MEDPLUS.BO plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, MEDPLUS.BO stands at 102.8B. In comparison, KPL.BO has a market cap of 14.9B. Regarding current trading prices, MEDPLUS.BO is priced at ₹835.45, while KPL.BO trades at ₹1,339.30.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
MEDPLUS.BO currently has a P/E ratio of 49.65, whereas KPL.BO's P/E ratio is 26.37. In terms of profitability, MEDPLUS.BO's ROE is +0.12%, compared to KPL.BO's ROE of +0.21%. Regarding short-term risk, MEDPLUS.BO is less volatile compared to KPL.BO. This indicates potentially lower risk in terms of short-term price fluctuations for MEDPLUS.BO.Check KPL.BO's competition here
MEDPLUS.BO vs SASTASUNDR.NS Comparison February 2026
MEDPLUS.BO plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, MEDPLUS.BO stands at 102.8B. In comparison, SASTASUNDR.NS has a market cap of 9B. Regarding current trading prices, MEDPLUS.BO is priced at ₹835.45, while SASTASUNDR.NS trades at ₹280.85.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
MEDPLUS.BO currently has a P/E ratio of 49.65, whereas SASTASUNDR.NS's P/E ratio is 34.66. In terms of profitability, MEDPLUS.BO's ROE is +0.12%, compared to SASTASUNDR.NS's ROE of +0.03%. Regarding short-term risk, MEDPLUS.BO is less volatile compared to SASTASUNDR.NS. This indicates potentially lower risk in terms of short-term price fluctuations for MEDPLUS.BO.Check SASTASUNDR.NS's competition here
MEDPLUS.BO vs SASTASUNDR.BO Comparison February 2026
MEDPLUS.BO plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, MEDPLUS.BO stands at 102.8B. In comparison, SASTASUNDR.BO has a market cap of 9B. Regarding current trading prices, MEDPLUS.BO is priced at ₹835.45, while SASTASUNDR.BO trades at ₹279.60.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
MEDPLUS.BO currently has a P/E ratio of 49.65, whereas SASTASUNDR.BO's P/E ratio is 34.60. In terms of profitability, MEDPLUS.BO's ROE is +0.12%, compared to SASTASUNDR.BO's ROE of +0.03%. Regarding short-term risk, MEDPLUS.BO is more volatile compared to SASTASUNDR.BO. This indicates potentially higher risk in terms of short-term price fluctuations for MEDPLUS.BO.Check SASTASUNDR.BO's competition here
MEDPLUS.BO vs FREDUN.BO Comparison February 2026
MEDPLUS.BO plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, MEDPLUS.BO stands at 102.8B. In comparison, FREDUN.BO has a market cap of 7.8B. Regarding current trading prices, MEDPLUS.BO is priced at ₹835.45, while FREDUN.BO trades at ₹1,646.60.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
MEDPLUS.BO currently has a P/E ratio of 49.65, whereas FREDUN.BO's P/E ratio is 23.53. In terms of profitability, MEDPLUS.BO's ROE is +0.12%, compared to FREDUN.BO's ROE of +0.23%. Regarding short-term risk, MEDPLUS.BO is less volatile compared to FREDUN.BO. This indicates potentially lower risk in terms of short-term price fluctuations for MEDPLUS.BO.Check FREDUN.BO's competition here
MEDPLUS.BO vs BPLPHARMA.BO Comparison February 2026
MEDPLUS.BO plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, MEDPLUS.BO stands at 102.8B. In comparison, BPLPHARMA.BO has a market cap of 7.7B. Regarding current trading prices, MEDPLUS.BO is priced at ₹835.45, while BPLPHARMA.BO trades at ₹1,095.00.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
MEDPLUS.BO currently has a P/E ratio of 49.65, whereas BPLPHARMA.BO's P/E ratio is -26.16. In terms of profitability, MEDPLUS.BO's ROE is +0.12%, compared to BPLPHARMA.BO's ROE of -0.02%. Regarding short-term risk, MEDPLUS.BO is less volatile compared to BPLPHARMA.BO. This indicates potentially lower risk in terms of short-term price fluctuations for MEDPLUS.BO.Check BPLPHARMA.BO's competition here
MEDPLUS.BO vs ANUHPHR.BO Comparison February 2026
MEDPLUS.BO plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, MEDPLUS.BO stands at 102.8B. In comparison, ANUHPHR.BO has a market cap of 7.6B. Regarding current trading prices, MEDPLUS.BO is priced at ₹835.45, while ANUHPHR.BO trades at ₹75.34.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
MEDPLUS.BO currently has a P/E ratio of 49.65, whereas ANUHPHR.BO's P/E ratio is 18.21. In terms of profitability, MEDPLUS.BO's ROE is +0.12%, compared to ANUHPHR.BO's ROE of +0.13%. Regarding short-term risk, MEDPLUS.BO is less volatile compared to ANUHPHR.BO. This indicates potentially lower risk in terms of short-term price fluctuations for MEDPLUS.BO.Check ANUHPHR.BO's competition here
MEDPLUS.BO vs PRAVEG.BO Comparison February 2026
MEDPLUS.BO plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, MEDPLUS.BO stands at 102.8B. In comparison, PRAVEG.BO has a market cap of 6.7B. Regarding current trading prices, MEDPLUS.BO is priced at ₹835.45, while PRAVEG.BO trades at ₹261.60.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
MEDPLUS.BO currently has a P/E ratio of 49.65, whereas PRAVEG.BO's P/E ratio is -273.19. In terms of profitability, MEDPLUS.BO's ROE is +0.12%, compared to PRAVEG.BO's ROE of -0.01%. Regarding short-term risk, MEDPLUS.BO is less volatile compared to PRAVEG.BO. This indicates potentially lower risk in terms of short-term price fluctuations for MEDPLUS.BO.Check PRAVEG.BO's competition here
MEDPLUS.BO vs SGRL.BO Comparison February 2026
MEDPLUS.BO plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, MEDPLUS.BO stands at 102.8B. In comparison, SGRL.BO has a market cap of 6.7B. Regarding current trading prices, MEDPLUS.BO is priced at ₹835.45, while SGRL.BO trades at ₹518.75.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
MEDPLUS.BO currently has a P/E ratio of 49.65, whereas SGRL.BO's P/E ratio is 36.85. In terms of profitability, MEDPLUS.BO's ROE is +0.12%, compared to SGRL.BO's ROE of +0.13%. Regarding short-term risk, MEDPLUS.BO is less volatile compared to SGRL.BO. This indicates potentially lower risk in terms of short-term price fluctuations for MEDPLUS.BO.Check SGRL.BO's competition here
MEDPLUS.BO vs SUDARSHAN.BO Comparison February 2026
MEDPLUS.BO plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, MEDPLUS.BO stands at 102.8B. In comparison, SUDARSHAN.BO has a market cap of 6.3B. Regarding current trading prices, MEDPLUS.BO is priced at ₹835.45, while SUDARSHAN.BO trades at ₹26.90.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
MEDPLUS.BO currently has a P/E ratio of 49.65, whereas SUDARSHAN.BO's P/E ratio is 31.21. In terms of profitability, MEDPLUS.BO's ROE is +0.12%, compared to SUDARSHAN.BO's ROE of +0.16%. Regarding short-term risk, MEDPLUS.BO is less volatile compared to SUDARSHAN.BO. This indicates potentially lower risk in terms of short-term price fluctuations for MEDPLUS.BO.Check SUDARSHAN.BO's competition here
MEDPLUS.BO vs ALBERTDA.BO Comparison February 2026
MEDPLUS.BO plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, MEDPLUS.BO stands at 102.8B. In comparison, ALBERTDA.BO has a market cap of 6.2B. Regarding current trading prices, MEDPLUS.BO is priced at ₹835.45, while ALBERTDA.BO trades at ₹1,084.85.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
MEDPLUS.BO currently has a P/E ratio of 49.65, whereas ALBERTDA.BO's P/E ratio is 32.30. In terms of profitability, MEDPLUS.BO's ROE is +0.12%, compared to ALBERTDA.BO's ROE of +0.02%. Regarding short-term risk, MEDPLUS.BO is less volatile compared to ALBERTDA.BO. This indicates potentially lower risk in terms of short-term price fluctuations for MEDPLUS.BO.Check ALBERTDA.BO's competition here
MEDPLUS.BO vs VIKRAMTH.BO Comparison February 2026
MEDPLUS.BO plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, MEDPLUS.BO stands at 102.8B. In comparison, VIKRAMTH.BO has a market cap of 4.8B. Regarding current trading prices, MEDPLUS.BO is priced at ₹835.45, while VIKRAMTH.BO trades at ₹151.60.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
MEDPLUS.BO currently has a P/E ratio of 49.65, whereas VIKRAMTH.BO's P/E ratio is 14.01. In terms of profitability, MEDPLUS.BO's ROE is +0.12%, compared to VIKRAMTH.BO's ROE of +0.28%. Regarding short-term risk, MEDPLUS.BO is less volatile compared to VIKRAMTH.BO. This indicates potentially lower risk in terms of short-term price fluctuations for MEDPLUS.BO.Check VIKRAMTH.BO's competition here
MEDPLUS.BO vs JENBURPH.BO Comparison February 2026
MEDPLUS.BO plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, MEDPLUS.BO stands at 102.8B. In comparison, JENBURPH.BO has a market cap of 4.4B. Regarding current trading prices, MEDPLUS.BO is priced at ₹835.45, while JENBURPH.BO trades at ₹996.30.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
MEDPLUS.BO currently has a P/E ratio of 49.65, whereas JENBURPH.BO's P/E ratio is 13.67. In terms of profitability, MEDPLUS.BO's ROE is +0.12%, compared to JENBURPH.BO's ROE of +0.19%. Regarding short-term risk, MEDPLUS.BO is less volatile compared to JENBURPH.BO. This indicates potentially lower risk in terms of short-term price fluctuations for MEDPLUS.BO.Check JENBURPH.BO's competition here
MEDPLUS.BO vs TLL.BO Comparison February 2026
MEDPLUS.BO plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, MEDPLUS.BO stands at 102.8B. In comparison, TLL.BO has a market cap of 3.1B. Regarding current trading prices, MEDPLUS.BO is priced at ₹835.45, while TLL.BO trades at ₹275.90.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
MEDPLUS.BO currently has a P/E ratio of 49.65, whereas TLL.BO's P/E ratio is 20.74. In terms of profitability, MEDPLUS.BO's ROE is +0.12%, compared to TLL.BO's ROE of +0.24%. Regarding short-term risk, MEDPLUS.BO is more volatile compared to TLL.BO. This indicates potentially higher risk in terms of short-term price fluctuations for MEDPLUS.BO.Check TLL.BO's competition here
MEDPLUS.BO vs ZENOTECH.BO Comparison February 2026
MEDPLUS.BO plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, MEDPLUS.BO stands at 102.8B. In comparison, ZENOTECH.BO has a market cap of 2.8B. Regarding current trading prices, MEDPLUS.BO is priced at ₹835.45, while ZENOTECH.BO trades at ₹45.07.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
MEDPLUS.BO currently has a P/E ratio of 49.65, whereas ZENOTECH.BO's P/E ratio is 82.33. In terms of profitability, MEDPLUS.BO's ROE is +0.12%, compared to ZENOTECH.BO's ROE of +0.03%. Regarding short-term risk, MEDPLUS.BO is less volatile compared to ZENOTECH.BO. This indicates potentially lower risk in terms of short-term price fluctuations for MEDPLUS.BO.Check ZENOTECH.BO's competition here
MEDPLUS.BO vs GENNEX.BO Comparison February 2026
MEDPLUS.BO plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, MEDPLUS.BO stands at 102.8B. In comparison, GENNEX.BO has a market cap of 2.7B. Regarding current trading prices, MEDPLUS.BO is priced at ₹835.45, while GENNEX.BO trades at ₹11.60.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
MEDPLUS.BO currently has a P/E ratio of 49.65, whereas GENNEX.BO's P/E ratio is 15.14. In terms of profitability, MEDPLUS.BO's ROE is +0.12%, compared to GENNEX.BO's ROE of +0.09%. Regarding short-term risk, MEDPLUS.BO is less volatile compared to GENNEX.BO. This indicates potentially lower risk in terms of short-term price fluctuations for MEDPLUS.BO.Check GENNEX.BO's competition here
MEDPLUS.BO vs KERALAYUR.BO Comparison February 2026
MEDPLUS.BO plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, MEDPLUS.BO stands at 102.8B. In comparison, KERALAYUR.BO has a market cap of 2.6B. Regarding current trading prices, MEDPLUS.BO is priced at ₹835.45, while KERALAYUR.BO trades at ₹218.95.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
MEDPLUS.BO currently has a P/E ratio of 49.65, whereas KERALAYUR.BO's P/E ratio is -11.10. In terms of profitability, MEDPLUS.BO's ROE is +0.12%, compared to KERALAYUR.BO's ROE of -1.45%. Regarding short-term risk, MEDPLUS.BO is less volatile compared to KERALAYUR.BO. This indicates potentially lower risk in terms of short-term price fluctuations for MEDPLUS.BO.Check KERALAYUR.BO's competition here
MEDPLUS.BO vs BDH.BO Comparison February 2026
MEDPLUS.BO plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, MEDPLUS.BO stands at 102.8B. In comparison, BDH.BO has a market cap of 2.4B. Regarding current trading prices, MEDPLUS.BO is priced at ₹835.45, while BDH.BO trades at ₹421.95.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
MEDPLUS.BO currently has a P/E ratio of 49.65, whereas BDH.BO's P/E ratio is 23.20. In terms of profitability, MEDPLUS.BO's ROE is +0.12%, compared to BDH.BO's ROE of +0.15%. Regarding short-term risk, MEDPLUS.BO is less volatile compared to BDH.BO. This indicates potentially lower risk in terms of short-term price fluctuations for MEDPLUS.BO.Check BDH.BO's competition here
MEDPLUS.BO vs SANJIVIN.BO Comparison February 2026
MEDPLUS.BO plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, MEDPLUS.BO stands at 102.8B. In comparison, SANJIVIN.BO has a market cap of 2.4B. Regarding current trading prices, MEDPLUS.BO is priced at ₹835.45, while SANJIVIN.BO trades at ₹195.40.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
MEDPLUS.BO currently has a P/E ratio of 49.65, whereas SANJIVIN.BO's P/E ratio is 32.61. In terms of profitability, MEDPLUS.BO's ROE is +0.12%, compared to SANJIVIN.BO's ROE of +0.22%. Regarding short-term risk, MEDPLUS.BO is more volatile compared to SANJIVIN.BO. This indicates potentially higher risk in terms of short-term price fluctuations for MEDPLUS.BO.Check SANJIVIN.BO's competition here
MEDPLUS.BO vs SYSCHEM.BO Comparison February 2026
MEDPLUS.BO plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, MEDPLUS.BO stands at 102.8B. In comparison, SYSCHEM.BO has a market cap of 2.2B. Regarding current trading prices, MEDPLUS.BO is priced at ₹835.45, while SYSCHEM.BO trades at ₹50.96.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
MEDPLUS.BO currently has a P/E ratio of 49.65, whereas SYSCHEM.BO's P/E ratio is 34.03. In terms of profitability, MEDPLUS.BO's ROE is +0.12%, compared to SYSCHEM.BO's ROE of +0.10%. Regarding short-term risk, MEDPLUS.BO is less volatile compared to SYSCHEM.BO. This indicates potentially lower risk in terms of short-term price fluctuations for MEDPLUS.BO.Check SYSCHEM.BO's competition here
MEDPLUS.BO vs TRANSCHEM.BO Comparison February 2026
MEDPLUS.BO plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, MEDPLUS.BO stands at 102.8B. In comparison, TRANSCHEM.BO has a market cap of 2.2B. Regarding current trading prices, MEDPLUS.BO is priced at ₹835.45, while TRANSCHEM.BO trades at ₹174.05.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
MEDPLUS.BO currently has a P/E ratio of 49.65, whereas TRANSCHEM.BO's P/E ratio is 74.27. In terms of profitability, MEDPLUS.BO's ROE is +0.12%, compared to TRANSCHEM.BO's ROE of +0.04%. Regarding short-term risk, MEDPLUS.BO is less volatile compared to TRANSCHEM.BO. This indicates potentially lower risk in terms of short-term price fluctuations for MEDPLUS.BO.Check TRANSCHEM.BO's competition here
MEDPLUS.BO vs AMBALALSA.BO Comparison February 2026
MEDPLUS.BO plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, MEDPLUS.BO stands at 102.8B. In comparison, AMBALALSA.BO has a market cap of 2B. Regarding current trading prices, MEDPLUS.BO is priced at ₹835.45, while AMBALALSA.BO trades at ₹26.48.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
MEDPLUS.BO currently has a P/E ratio of 49.65, whereas AMBALALSA.BO's P/E ratio is 21.28. In terms of profitability, MEDPLUS.BO's ROE is +0.12%, compared to AMBALALSA.BO's ROE of +0.08%. Regarding short-term risk, MEDPLUS.BO is less volatile compared to AMBALALSA.BO. This indicates potentially lower risk in terms of short-term price fluctuations for MEDPLUS.BO.Check AMBALALSA.BO's competition here
MEDPLUS.BO vs OXYGENTAPH.BO Comparison February 2026
MEDPLUS.BO plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, MEDPLUS.BO stands at 102.8B. In comparison, OXYGENTAPH.BO has a market cap of 1.9B. Regarding current trading prices, MEDPLUS.BO is priced at ₹835.45, while OXYGENTAPH.BO trades at ₹50.36.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
MEDPLUS.BO currently has a P/E ratio of 49.65, whereas OXYGENTAPH.BO's P/E ratio is -10.71. In terms of profitability, MEDPLUS.BO's ROE is +0.12%, compared to OXYGENTAPH.BO's ROE of +0.65%. Regarding short-term risk, MEDPLUS.BO is less volatile compared to OXYGENTAPH.BO. This indicates potentially lower risk in terms of short-term price fluctuations for MEDPLUS.BO.Check OXYGENTAPH.BO's competition here
MEDPLUS.BO vs AUROLAB.BO Comparison February 2026
MEDPLUS.BO plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, MEDPLUS.BO stands at 102.8B. In comparison, AUROLAB.BO has a market cap of 1.8B. Regarding current trading prices, MEDPLUS.BO is priced at ₹835.45, while AUROLAB.BO trades at ₹293.85.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
MEDPLUS.BO currently has a P/E ratio of 49.65, whereas AUROLAB.BO's P/E ratio is 55.85. In terms of profitability, MEDPLUS.BO's ROE is +0.12%, compared to AUROLAB.BO's ROE of +0.07%. Regarding short-term risk, MEDPLUS.BO is less volatile compared to AUROLAB.BO. This indicates potentially lower risk in terms of short-term price fluctuations for MEDPLUS.BO.Check AUROLAB.BO's competition here
MEDPLUS.BO vs NATCAPSUQ.BO Comparison February 2026
MEDPLUS.BO plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, MEDPLUS.BO stands at 102.8B. In comparison, NATCAPSUQ.BO has a market cap of 1.6B. Regarding current trading prices, MEDPLUS.BO is priced at ₹835.45, while NATCAPSUQ.BO trades at ₹156.45.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
MEDPLUS.BO currently has a P/E ratio of 49.65, whereas NATCAPSUQ.BO's P/E ratio is -13.64. In terms of profitability, MEDPLUS.BO's ROE is +0.12%, compared to NATCAPSUQ.BO's ROE of -0.08%. Regarding short-term risk, MEDPLUS.BO is less volatile compared to NATCAPSUQ.BO. This indicates potentially lower risk in terms of short-term price fluctuations for MEDPLUS.BO.Check NATCAPSUQ.BO's competition here
MEDPLUS.BO vs CORALAB.BO Comparison February 2026
MEDPLUS.BO plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, MEDPLUS.BO stands at 102.8B. In comparison, CORALAB.BO has a market cap of 1.5B. Regarding current trading prices, MEDPLUS.BO is priced at ₹835.45, while CORALAB.BO trades at ₹430.70.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
MEDPLUS.BO currently has a P/E ratio of 49.65, whereas CORALAB.BO's P/E ratio is 8.89. In terms of profitability, MEDPLUS.BO's ROE is +0.12%, compared to CORALAB.BO's ROE of +0.07%. Regarding short-term risk, MEDPLUS.BO is less volatile compared to CORALAB.BO. This indicates potentially lower risk in terms of short-term price fluctuations for MEDPLUS.BO.Check CORALAB.BO's competition here
MEDPLUS.BO vs KIMIABL.BO Comparison February 2026
MEDPLUS.BO plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, MEDPLUS.BO stands at 102.8B. In comparison, KIMIABL.BO has a market cap of 1.5B. Regarding current trading prices, MEDPLUS.BO is priced at ₹835.45, while KIMIABL.BO trades at ₹30.16.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
MEDPLUS.BO currently has a P/E ratio of 49.65, whereas KIMIABL.BO's P/E ratio is N/A. In terms of profitability, MEDPLUS.BO's ROE is +0.12%, compared to KIMIABL.BO's ROE of +1.10%. Regarding short-term risk, MEDPLUS.BO is less volatile compared to KIMIABL.BO. This indicates potentially lower risk in terms of short-term price fluctuations for MEDPLUS.BO.Check KIMIABL.BO's competition here
MEDPLUS.BO vs PARNAXLAB.BO Comparison February 2026
MEDPLUS.BO plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, MEDPLUS.BO stands at 102.8B. In comparison, PARNAXLAB.BO has a market cap of 1.5B. Regarding current trading prices, MEDPLUS.BO is priced at ₹835.45, while PARNAXLAB.BO trades at ₹130.00.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
MEDPLUS.BO currently has a P/E ratio of 49.65, whereas PARNAXLAB.BO's P/E ratio is 13.71. In terms of profitability, MEDPLUS.BO's ROE is +0.12%, compared to PARNAXLAB.BO's ROE of +0.15%. Regarding short-term risk, MEDPLUS.BO is less volatile compared to PARNAXLAB.BO. This indicates potentially lower risk in terms of short-term price fluctuations for MEDPLUS.BO.Check PARNAXLAB.BO's competition here
MEDPLUS.BO vs PANCHSHEEL.BO Comparison February 2026
MEDPLUS.BO plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, MEDPLUS.BO stands at 102.8B. In comparison, PANCHSHEEL.BO has a market cap of 1.4B. Regarding current trading prices, MEDPLUS.BO is priced at ₹835.45, while PANCHSHEEL.BO trades at ₹110.00.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
MEDPLUS.BO currently has a P/E ratio of 49.65, whereas PANCHSHEEL.BO's P/E ratio is 11.94. In terms of profitability, MEDPLUS.BO's ROE is +0.12%, compared to PANCHSHEEL.BO's ROE of +0.09%. Regarding short-term risk, MEDPLUS.BO is more volatile compared to PANCHSHEEL.BO. This indicates potentially higher risk in terms of short-term price fluctuations for MEDPLUS.BO.Check PANCHSHEEL.BO's competition here
MEDPLUS.BO vs SMRUTHIORG.BO Comparison February 2026
MEDPLUS.BO plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, MEDPLUS.BO stands at 102.8B. In comparison, SMRUTHIORG.BO has a market cap of 1.3B. Regarding current trading prices, MEDPLUS.BO is priced at ₹835.45, while SMRUTHIORG.BO trades at ₹112.75.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
MEDPLUS.BO currently has a P/E ratio of 49.65, whereas SMRUTHIORG.BO's P/E ratio is 27.94. In terms of profitability, MEDPLUS.BO's ROE is +0.12%, compared to SMRUTHIORG.BO's ROE of +0.07%. Regarding short-term risk, MEDPLUS.BO is less volatile compared to SMRUTHIORG.BO. This indicates potentially lower risk in terms of short-term price fluctuations for MEDPLUS.BO.Check SMRUTHIORG.BO's competition here
MEDPLUS.BO vs PHARMAID.BO Comparison February 2026
MEDPLUS.BO plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, MEDPLUS.BO stands at 102.8B. In comparison, PHARMAID.BO has a market cap of 1.2B. Regarding current trading prices, MEDPLUS.BO is priced at ₹835.45, while PHARMAID.BO trades at ₹33.90.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
MEDPLUS.BO currently has a P/E ratio of 49.65, whereas PHARMAID.BO's P/E ratio is -9.92. In terms of profitability, MEDPLUS.BO's ROE is +0.12%, compared to PHARMAID.BO's ROE of -0.24%. Regarding short-term risk, MEDPLUS.BO is less volatile compared to PHARMAID.BO. This indicates potentially lower risk in terms of short-term price fluctuations for MEDPLUS.BO.Check PHARMAID.BO's competition here
MEDPLUS.BO vs LACTOSE.BO Comparison February 2026
MEDPLUS.BO plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, MEDPLUS.BO stands at 102.8B. In comparison, LACTOSE.BO has a market cap of 1.2B. Regarding current trading prices, MEDPLUS.BO is priced at ₹835.45, while LACTOSE.BO trades at ₹96.02.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
MEDPLUS.BO currently has a P/E ratio of 49.65, whereas LACTOSE.BO's P/E ratio is 42.06. In terms of profitability, MEDPLUS.BO's ROE is +0.12%, compared to LACTOSE.BO's ROE of +0.08%. Regarding short-term risk, MEDPLUS.BO is less volatile compared to LACTOSE.BO. This indicates potentially lower risk in terms of short-term price fluctuations for MEDPLUS.BO.Check LACTOSE.BO's competition here
MEDPLUS.BO vs TYCHE.BO Comparison February 2026
MEDPLUS.BO plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, MEDPLUS.BO stands at 102.8B. In comparison, TYCHE.BO has a market cap of 1.2B. Regarding current trading prices, MEDPLUS.BO is priced at ₹835.45, while TYCHE.BO trades at ₹117.05.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
MEDPLUS.BO currently has a P/E ratio of 49.65, whereas TYCHE.BO's P/E ratio is 11.86. In terms of profitability, MEDPLUS.BO's ROE is +0.12%, compared to TYCHE.BO's ROE of +0.05%. Regarding short-term risk, MEDPLUS.BO is less volatile compared to TYCHE.BO. This indicates potentially lower risk in terms of short-term price fluctuations for MEDPLUS.BO.Check TYCHE.BO's competition here
MEDPLUS.BO vs DENISCHEM.BO Comparison February 2026
MEDPLUS.BO plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, MEDPLUS.BO stands at 102.8B. In comparison, DENISCHEM.BO has a market cap of 1B. Regarding current trading prices, MEDPLUS.BO is priced at ₹835.45, while DENISCHEM.BO trades at ₹76.20.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
MEDPLUS.BO currently has a P/E ratio of 49.65, whereas DENISCHEM.BO's P/E ratio is 14.54. In terms of profitability, MEDPLUS.BO's ROE is +0.12%, compared to DENISCHEM.BO's ROE of +0.10%. Regarding short-term risk, MEDPLUS.BO is less volatile compared to DENISCHEM.BO. This indicates potentially lower risk in terms of short-term price fluctuations for MEDPLUS.BO.Check DENISCHEM.BO's competition here
MEDPLUS.BO vs MERCURYLAB.BO Comparison February 2026
MEDPLUS.BO plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, MEDPLUS.BO stands at 102.8B. In comparison, MERCURYLAB.BO has a market cap of 1B. Regarding current trading prices, MEDPLUS.BO is priced at ₹835.45, while MERCURYLAB.BO trades at ₹801.55.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
MEDPLUS.BO currently has a P/E ratio of 49.65, whereas MERCURYLAB.BO's P/E ratio is 21.34. In terms of profitability, MEDPLUS.BO's ROE is +0.12%, compared to MERCURYLAB.BO's ROE of +0.09%. Regarding short-term risk, MEDPLUS.BO is less volatile compared to MERCURYLAB.BO. This indicates potentially lower risk in terms of short-term price fluctuations for MEDPLUS.BO.Check MERCURYLAB.BO's competition here
MEDPLUS.BO vs MAKERSL.BO Comparison February 2026
MEDPLUS.BO plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, MEDPLUS.BO stands at 102.8B. In comparison, MAKERSL.BO has a market cap of 947.6M. Regarding current trading prices, MEDPLUS.BO is priced at ₹835.45, while MAKERSL.BO trades at ₹141.10.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
MEDPLUS.BO currently has a P/E ratio of 49.65, whereas MAKERSL.BO's P/E ratio is 77.96. In terms of profitability, MEDPLUS.BO's ROE is +0.12%, compared to MAKERSL.BO's ROE of +0.01%. Regarding short-term risk, MEDPLUS.BO is less volatile compared to MAKERSL.BO. This indicates potentially lower risk in terms of short-term price fluctuations for MEDPLUS.BO.Check MAKERSL.BO's competition here
MEDPLUS.BO vs SOURCENTRL.BO Comparison February 2026
MEDPLUS.BO plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, MEDPLUS.BO stands at 102.8B. In comparison, SOURCENTRL.BO has a market cap of 849.4M. Regarding current trading prices, MEDPLUS.BO is priced at ₹835.45, while SOURCENTRL.BO trades at ₹132.65.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
MEDPLUS.BO currently has a P/E ratio of 49.65, whereas SOURCENTRL.BO's P/E ratio is 28.56. In terms of profitability, MEDPLUS.BO's ROE is +0.12%, compared to SOURCENTRL.BO's ROE of +0.12%. Regarding short-term risk, MEDPLUS.BO is less volatile compared to SOURCENTRL.BO. This indicates potentially lower risk in terms of short-term price fluctuations for MEDPLUS.BO.Check SOURCENTRL.BO's competition here
MEDPLUS.BO vs BIBCL.BO Comparison February 2026
MEDPLUS.BO plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, MEDPLUS.BO stands at 102.8B. In comparison, BIBCL.BO has a market cap of 769.5M. Regarding current trading prices, MEDPLUS.BO is priced at ₹835.45, while BIBCL.BO trades at ₹17.82.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
MEDPLUS.BO currently has a P/E ratio of 49.65, whereas BIBCL.BO's P/E ratio is -4.80. In terms of profitability, MEDPLUS.BO's ROE is +0.12%, compared to BIBCL.BO's ROE of -0.17%. Regarding short-term risk, MEDPLUS.BO is less volatile compared to BIBCL.BO. This indicates potentially lower risk in terms of short-term price fluctuations for MEDPLUS.BO.Check BIBCL.BO's competition here
MEDPLUS.BO vs CONCORD.BO Comparison February 2026
MEDPLUS.BO plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, MEDPLUS.BO stands at 102.8B. In comparison, CONCORD.BO has a market cap of 746.2M. Regarding current trading prices, MEDPLUS.BO is priced at ₹835.45, while CONCORD.BO trades at ₹76.88.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
MEDPLUS.BO currently has a P/E ratio of 49.65, whereas CONCORD.BO's P/E ratio is 129.29. In terms of profitability, MEDPLUS.BO's ROE is +0.12%, compared to CONCORD.BO's ROE of +0.02%. Regarding short-term risk, MEDPLUS.BO is less volatile compared to CONCORD.BO. This indicates potentially lower risk in terms of short-term price fluctuations for MEDPLUS.BO.Check CONCORD.BO's competition here
MEDPLUS.BO vs BACPHAR.BO Comparison February 2026
MEDPLUS.BO plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, MEDPLUS.BO stands at 102.8B. In comparison, BACPHAR.BO has a market cap of 713.8M. Regarding current trading prices, MEDPLUS.BO is priced at ₹835.45, while BACPHAR.BO trades at ₹50.00.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
MEDPLUS.BO currently has a P/E ratio of 49.65, whereas BACPHAR.BO's P/E ratio is 134.41. In terms of profitability, MEDPLUS.BO's ROE is +0.12%, compared to BACPHAR.BO's ROE of +0.04%. Regarding short-term risk, MEDPLUS.BO is less volatile compared to BACPHAR.BO. This indicates potentially lower risk in terms of short-term price fluctuations for MEDPLUS.BO.Check BACPHAR.BO's competition here
MEDPLUS.BO vs SUNLOC.BO Comparison February 2026
MEDPLUS.BO plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, MEDPLUS.BO stands at 102.8B. In comparison, SUNLOC.BO has a market cap of 661.7M. Regarding current trading prices, MEDPLUS.BO is priced at ₹835.45, while SUNLOC.BO trades at ₹65.35.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
MEDPLUS.BO currently has a P/E ratio of 49.65, whereas SUNLOC.BO's P/E ratio is 23.13. In terms of profitability, MEDPLUS.BO's ROE is +0.12%, compared to SUNLOC.BO's ROE of +0.04%. Regarding short-term risk, MEDPLUS.BO is less volatile compared to SUNLOC.BO. This indicates potentially lower risk in terms of short-term price fluctuations for MEDPLUS.BO.Check SUNLOC.BO's competition here
MEDPLUS.BO vs PHRMASI.BO Comparison February 2026
MEDPLUS.BO plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, MEDPLUS.BO stands at 102.8B. In comparison, PHRMASI.BO has a market cap of 634.9M. Regarding current trading prices, MEDPLUS.BO is priced at ₹835.45, while PHRMASI.BO trades at ₹96.90.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
MEDPLUS.BO currently has a P/E ratio of 49.65, whereas PHRMASI.BO's P/E ratio is 3.58. In terms of profitability, MEDPLUS.BO's ROE is +0.12%, compared to PHRMASI.BO's ROE of +1.86%. Regarding short-term risk, MEDPLUS.BO is more volatile compared to PHRMASI.BO. This indicates potentially higher risk in terms of short-term price fluctuations for MEDPLUS.BO.Check PHRMASI.BO's competition here
MEDPLUS.BO vs GODAVARI.BO Comparison February 2026
MEDPLUS.BO plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, MEDPLUS.BO stands at 102.8B. In comparison, GODAVARI.BO has a market cap of 595.6M. Regarding current trading prices, MEDPLUS.BO is priced at ₹835.45, while GODAVARI.BO trades at ₹80.91.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
MEDPLUS.BO currently has a P/E ratio of 49.65, whereas GODAVARI.BO's P/E ratio is -86.91. In terms of profitability, MEDPLUS.BO's ROE is +0.12%, compared to GODAVARI.BO's ROE of +0.08%. Regarding short-term risk, MEDPLUS.BO is less volatile compared to GODAVARI.BO. This indicates potentially lower risk in terms of short-term price fluctuations for MEDPLUS.BO.Check GODAVARI.BO's competition here
MEDPLUS.BO vs PANJON.BO Comparison February 2026
MEDPLUS.BO plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, MEDPLUS.BO stands at 102.8B. In comparison, PANJON.BO has a market cap of 502.2M. Regarding current trading prices, MEDPLUS.BO is priced at ₹835.45, while PANJON.BO trades at ₹29.00.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
MEDPLUS.BO currently has a P/E ratio of 49.65, whereas PANJON.BO's P/E ratio is 117.04. In terms of profitability, MEDPLUS.BO's ROE is +0.12%, compared to PANJON.BO's ROE of +0.05%. Regarding short-term risk, MEDPLUS.BO is less volatile compared to PANJON.BO. This indicates potentially lower risk in terms of short-term price fluctuations for MEDPLUS.BO.Check PANJON.BO's competition here
MEDPLUS.BO vs VISTAPH.BO Comparison February 2026
MEDPLUS.BO plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, MEDPLUS.BO stands at 102.8B. In comparison, VISTAPH.BO has a market cap of 418.6M. Regarding current trading prices, MEDPLUS.BO is priced at ₹835.45, while VISTAPH.BO trades at ₹7.18.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
MEDPLUS.BO currently has a P/E ratio of 49.65, whereas VISTAPH.BO's P/E ratio is -5.96. In terms of profitability, MEDPLUS.BO's ROE is +0.12%, compared to VISTAPH.BO's ROE of -0.17%. Regarding short-term risk, MEDPLUS.BO is less volatile compared to VISTAPH.BO. This indicates potentially lower risk in terms of short-term price fluctuations for MEDPLUS.BO.Check VISTAPH.BO's competition here
MEDPLUS.BO vs VRL.BO Comparison February 2026
MEDPLUS.BO plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, MEDPLUS.BO stands at 102.8B. In comparison, VRL.BO has a market cap of 416.7M. Regarding current trading prices, MEDPLUS.BO is priced at ₹835.45, while VRL.BO trades at ₹125.95.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
MEDPLUS.BO currently has a P/E ratio of 49.65, whereas VRL.BO's P/E ratio is 11.15. In terms of profitability, MEDPLUS.BO's ROE is +0.12%, compared to VRL.BO's ROE of +0.10%. Regarding short-term risk, MEDPLUS.BO is less volatile compared to VRL.BO. This indicates potentially lower risk in terms of short-term price fluctuations for MEDPLUS.BO.Check VRL.BO's competition here
MEDPLUS.BO vs SHELTER.BO Comparison February 2026
MEDPLUS.BO plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, MEDPLUS.BO stands at 102.8B. In comparison, SHELTER.BO has a market cap of 410.6M. Regarding current trading prices, MEDPLUS.BO is priced at ₹835.45, while SHELTER.BO trades at ₹35.00.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
MEDPLUS.BO currently has a P/E ratio of 49.65, whereas SHELTER.BO's P/E ratio is 6.56. In terms of profitability, MEDPLUS.BO's ROE is +0.12%, compared to SHELTER.BO's ROE of +0.12%. Regarding short-term risk, MEDPLUS.BO is less volatile compared to SHELTER.BO. This indicates potentially lower risk in terms of short-term price fluctuations for MEDPLUS.BO.Check SHELTER.BO's competition here
MEDPLUS.BO vs VEERHEALTH.BO Comparison February 2026
MEDPLUS.BO plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, MEDPLUS.BO stands at 102.8B. In comparison, VEERHEALTH.BO has a market cap of 397.4M. Regarding current trading prices, MEDPLUS.BO is priced at ₹835.45, while VEERHEALTH.BO trades at ₹19.63.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
MEDPLUS.BO currently has a P/E ratio of 49.65, whereas VEERHEALTH.BO's P/E ratio is 82.79. In terms of profitability, MEDPLUS.BO's ROE is +0.12%, compared to VEERHEALTH.BO's ROE of +0.04%. Regarding short-term risk, MEDPLUS.BO is less volatile compared to VEERHEALTH.BO. This indicates potentially lower risk in terms of short-term price fluctuations for MEDPLUS.BO.Check VEERHEALTH.BO's competition here
MEDPLUS.BO vs ROOPAIND.BO Comparison February 2026
MEDPLUS.BO plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, MEDPLUS.BO stands at 102.8B. In comparison, ROOPAIND.BO has a market cap of 348.3M. Regarding current trading prices, MEDPLUS.BO is priced at ₹835.45, while ROOPAIND.BO trades at ₹42.94.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
MEDPLUS.BO currently has a P/E ratio of 49.65, whereas ROOPAIND.BO's P/E ratio is 18.07. In terms of profitability, MEDPLUS.BO's ROE is +0.12%, compared to ROOPAIND.BO's ROE of +0.11%. Regarding short-term risk, MEDPLUS.BO is less volatile compared to ROOPAIND.BO. This indicates potentially lower risk in terms of short-term price fluctuations for MEDPLUS.BO.Check ROOPAIND.BO's competition here
MEDPLUS.BO vs SANDUPHQ.BO Comparison February 2026
MEDPLUS.BO plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, MEDPLUS.BO stands at 102.8B. In comparison, SANDUPHQ.BO has a market cap of 340.5M. Regarding current trading prices, MEDPLUS.BO is priced at ₹835.45, while SANDUPHQ.BO trades at ₹36.35.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
MEDPLUS.BO currently has a P/E ratio of 49.65, whereas SANDUPHQ.BO's P/E ratio is 20.98. In terms of profitability, MEDPLUS.BO's ROE is +0.12%, compared to SANDUPHQ.BO's ROE of +0.05%. Regarding short-term risk, MEDPLUS.BO is less volatile compared to SANDUPHQ.BO. This indicates potentially lower risk in terms of short-term price fluctuations for MEDPLUS.BO.Check SANDUPHQ.BO's competition here
MEDPLUS.BO vs DECCAN.BO Comparison February 2026
MEDPLUS.BO plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, MEDPLUS.BO stands at 102.8B. In comparison, DECCAN.BO has a market cap of 309M. Regarding current trading prices, MEDPLUS.BO is priced at ₹835.45, while DECCAN.BO trades at ₹13.42.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
MEDPLUS.BO currently has a P/E ratio of 49.65, whereas DECCAN.BO's P/E ratio is 23.14. In terms of profitability, MEDPLUS.BO's ROE is +0.12%, compared to DECCAN.BO's ROE of +0.02%. Regarding short-term risk, MEDPLUS.BO is less volatile compared to DECCAN.BO. This indicates potentially lower risk in terms of short-term price fluctuations for MEDPLUS.BO.Check DECCAN.BO's competition here
MEDPLUS.BO vs MEDICAPQ.BO Comparison February 2026
MEDPLUS.BO plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, MEDPLUS.BO stands at 102.8B. In comparison, MEDICAPQ.BO has a market cap of 299.3M. Regarding current trading prices, MEDPLUS.BO is priced at ₹835.45, while MEDICAPQ.BO trades at ₹24.30.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
MEDPLUS.BO currently has a P/E ratio of 49.65, whereas MEDICAPQ.BO's P/E ratio is -5.31. In terms of profitability, MEDPLUS.BO's ROE is +0.12%, compared to MEDICAPQ.BO's ROE of -0.04%. Regarding short-term risk, MEDPLUS.BO is less volatile compared to MEDICAPQ.BO. This indicates potentially lower risk in terms of short-term price fluctuations for MEDPLUS.BO.Check MEDICAPQ.BO's competition here
MEDPLUS.BO vs ANG.BO Comparison February 2026
MEDPLUS.BO plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, MEDPLUS.BO stands at 102.8B. In comparison, ANG.BO has a market cap of 296.8M. Regarding current trading prices, MEDPLUS.BO is priced at ₹835.45, while ANG.BO trades at ₹23.36.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
MEDPLUS.BO currently has a P/E ratio of 49.65, whereas ANG.BO's P/E ratio is -2.43. In terms of profitability, MEDPLUS.BO's ROE is +0.12%, compared to ANG.BO's ROE of -0.18%. Regarding short-term risk, MEDPLUS.BO is less volatile compared to ANG.BO. This indicates potentially lower risk in terms of short-term price fluctuations for MEDPLUS.BO.Check ANG.BO's competition here
MEDPLUS.BO vs GUJTERC.BO Comparison February 2026
MEDPLUS.BO plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, MEDPLUS.BO stands at 102.8B. In comparison, GUJTERC.BO has a market cap of 287.9M. Regarding current trading prices, MEDPLUS.BO is priced at ₹835.45, while GUJTERC.BO trades at ₹39.94.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
MEDPLUS.BO currently has a P/E ratio of 49.65, whereas GUJTERC.BO's P/E ratio is -20.75. In terms of profitability, MEDPLUS.BO's ROE is +0.12%, compared to GUJTERC.BO's ROE of -0.16%. Regarding short-term risk, MEDPLUS.BO is less volatile compared to GUJTERC.BO. This indicates potentially lower risk in terms of short-term price fluctuations for MEDPLUS.BO.Check GUJTERC.BO's competition here
MEDPLUS.BO vs CRSTCHM.BO Comparison February 2026
MEDPLUS.BO plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, MEDPLUS.BO stands at 102.8B. In comparison, CRSTCHM.BO has a market cap of 270.2M. Regarding current trading prices, MEDPLUS.BO is priced at ₹835.45, while CRSTCHM.BO trades at ₹91.00.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
MEDPLUS.BO currently has a P/E ratio of 49.65, whereas CRSTCHM.BO's P/E ratio is 13.34. In terms of profitability, MEDPLUS.BO's ROE is +0.12%, compared to CRSTCHM.BO's ROE of +0.30%. Regarding short-term risk, MEDPLUS.BO is more volatile compared to CRSTCHM.BO. This indicates potentially higher risk in terms of short-term price fluctuations for MEDPLUS.BO.Check CRSTCHM.BO's competition here
MEDPLUS.BO vs TRIMURTHI.BO Comparison February 2026
MEDPLUS.BO plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, MEDPLUS.BO stands at 102.8B. In comparison, TRIMURTHI.BO has a market cap of 264.8M. Regarding current trading prices, MEDPLUS.BO is priced at ₹835.45, while TRIMURTHI.BO trades at ₹26.61.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
MEDPLUS.BO currently has a P/E ratio of 49.65, whereas TRIMURTHI.BO's P/E ratio is 102.35. In terms of profitability, MEDPLUS.BO's ROE is +0.12%, compared to TRIMURTHI.BO's ROE of +0.04%. Regarding short-term risk, MEDPLUS.BO is more volatile compared to TRIMURTHI.BO. This indicates potentially higher risk in terms of short-term price fluctuations for MEDPLUS.BO.Check TRIMURTHI.BO's competition here
MEDPLUS.BO vs ASRL.BO Comparison February 2026
MEDPLUS.BO plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, MEDPLUS.BO stands at 102.8B. In comparison, ASRL.BO has a market cap of 219.4M. Regarding current trading prices, MEDPLUS.BO is priced at ₹835.45, while ASRL.BO trades at ₹7.71.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
MEDPLUS.BO currently has a P/E ratio of 49.65, whereas ASRL.BO's P/E ratio is 12.92. In terms of profitability, MEDPLUS.BO's ROE is +0.12%, compared to ASRL.BO's ROE of +0.01%. Regarding short-term risk, MEDPLUS.BO is less volatile compared to ASRL.BO. This indicates potentially lower risk in terms of short-term price fluctuations for MEDPLUS.BO.Check ASRL.BO's competition here
MEDPLUS.BO vs ISHITADR.BO Comparison February 2026
MEDPLUS.BO plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, MEDPLUS.BO stands at 102.8B. In comparison, ISHITADR.BO has a market cap of 207M. Regarding current trading prices, MEDPLUS.BO is priced at ₹835.45, while ISHITADR.BO trades at ₹69.00.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
MEDPLUS.BO currently has a P/E ratio of 49.65, whereas ISHITADR.BO's P/E ratio is 23.31. In terms of profitability, MEDPLUS.BO's ROE is +0.12%, compared to ISHITADR.BO's ROE of +0.08%. Regarding short-term risk, MEDPLUS.BO is less volatile compared to ISHITADR.BO. This indicates potentially lower risk in terms of short-term price fluctuations for MEDPLUS.BO.Check ISHITADR.BO's competition here
MEDPLUS.BO vs CHEMOPH.BO Comparison February 2026
MEDPLUS.BO plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, MEDPLUS.BO stands at 102.8B. In comparison, CHEMOPH.BO has a market cap of 196.3M. Regarding current trading prices, MEDPLUS.BO is priced at ₹835.45, while CHEMOPH.BO trades at ₹130.85.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
MEDPLUS.BO currently has a P/E ratio of 49.65, whereas CHEMOPH.BO's P/E ratio is -1.61. In terms of profitability, MEDPLUS.BO's ROE is +0.12%, compared to CHEMOPH.BO's ROE of -0.87%. Regarding short-term risk, MEDPLUS.BO is less volatile compared to CHEMOPH.BO. This indicates potentially lower risk in terms of short-term price fluctuations for MEDPLUS.BO.Check CHEMOPH.BO's competition here
MEDPLUS.BO vs ZENITHHE.BO Comparison February 2026
MEDPLUS.BO plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, MEDPLUS.BO stands at 102.8B. In comparison, ZENITHHE.BO has a market cap of 180M. Regarding current trading prices, MEDPLUS.BO is priced at ₹835.45, while ZENITHHE.BO trades at ₹3.29.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
MEDPLUS.BO currently has a P/E ratio of 49.65, whereas ZENITHHE.BO's P/E ratio is -335.00. In terms of profitability, MEDPLUS.BO's ROE is +0.12%, compared to ZENITHHE.BO's ROE of +0.06%. Regarding short-term risk, MEDPLUS.BO is less volatile compared to ZENITHHE.BO. This indicates potentially lower risk in terms of short-term price fluctuations for MEDPLUS.BO.Check ZENITHHE.BO's competition here
MEDPLUS.BO vs ZENLABS.BO Comparison February 2026
MEDPLUS.BO plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, MEDPLUS.BO stands at 102.8B. In comparison, ZENLABS.BO has a market cap of 136.1M. Regarding current trading prices, MEDPLUS.BO is priced at ₹835.45, while ZENLABS.BO trades at ₹19.96.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
MEDPLUS.BO currently has a P/E ratio of 49.65, whereas ZENLABS.BO's P/E ratio is -7.36. In terms of profitability, MEDPLUS.BO's ROE is +0.12%, compared to ZENLABS.BO's ROE of -0.18%. Regarding short-term risk, MEDPLUS.BO is less volatile compared to ZENLABS.BO. This indicates potentially lower risk in terms of short-term price fluctuations for MEDPLUS.BO.Check ZENLABS.BO's competition here
MEDPLUS.BO vs NORRIS.BO Comparison February 2026
MEDPLUS.BO plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, MEDPLUS.BO stands at 102.8B. In comparison, NORRIS.BO has a market cap of 135.4M. Regarding current trading prices, MEDPLUS.BO is priced at ₹835.45, while NORRIS.BO trades at ₹13.24.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
MEDPLUS.BO currently has a P/E ratio of 49.65, whereas NORRIS.BO's P/E ratio is N/A. In terms of profitability, MEDPLUS.BO's ROE is +0.12%, compared to NORRIS.BO's ROE of +0.08%. Regarding short-term risk, MEDPLUS.BO is less volatile compared to NORRIS.BO. This indicates potentially lower risk in terms of short-term price fluctuations for MEDPLUS.BO.Check NORRIS.BO's competition here
MEDPLUS.BO vs EMMESSA.BO Comparison February 2026
MEDPLUS.BO plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, MEDPLUS.BO stands at 102.8B. In comparison, EMMESSA.BO has a market cap of 126.4M. Regarding current trading prices, MEDPLUS.BO is priced at ₹835.45, while EMMESSA.BO trades at ₹25.25.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
MEDPLUS.BO currently has a P/E ratio of 49.65, whereas EMMESSA.BO's P/E ratio is 57.50. In terms of profitability, MEDPLUS.BO's ROE is +0.12%, compared to EMMESSA.BO's ROE of +0.04%. Regarding short-term risk, MEDPLUS.BO is less volatile compared to EMMESSA.BO. This indicates potentially lower risk in terms of short-term price fluctuations for MEDPLUS.BO.Check EMMESSA.BO's competition here
MEDPLUS.BO vs CHCL.BO Comparison February 2026
MEDPLUS.BO plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, MEDPLUS.BO stands at 102.8B. In comparison, CHCL.BO has a market cap of 125.2M. Regarding current trading prices, MEDPLUS.BO is priced at ₹835.45, while CHCL.BO trades at ₹5.01.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
MEDPLUS.BO currently has a P/E ratio of 49.65, whereas CHCL.BO's P/E ratio is -0.06. In terms of profitability, MEDPLUS.BO's ROE is +0.12%, compared to CHCL.BO's ROE of -0.21%. Regarding short-term risk, MEDPLUS.BO is more volatile compared to CHCL.BO. This indicates potentially higher risk in terms of short-term price fluctuations for MEDPLUS.BO.Check CHCL.BO's competition here
MEDPLUS.BO vs COLINZ.BO Comparison February 2026
MEDPLUS.BO plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, MEDPLUS.BO stands at 102.8B. In comparison, COLINZ.BO has a market cap of 116M. Regarding current trading prices, MEDPLUS.BO is priced at ₹835.45, while COLINZ.BO trades at ₹47.50.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
MEDPLUS.BO currently has a P/E ratio of 49.65, whereas COLINZ.BO's P/E ratio is 23.49. In terms of profitability, MEDPLUS.BO's ROE is +0.12%, compared to COLINZ.BO's ROE of +0.05%. Regarding short-term risk, MEDPLUS.BO is more volatile compared to COLINZ.BO. This indicates potentially higher risk in terms of short-term price fluctuations for MEDPLUS.BO.Check COLINZ.BO's competition here
MEDPLUS.BO vs DESHRAK.BO Comparison February 2026
MEDPLUS.BO plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, MEDPLUS.BO stands at 102.8B. In comparison, DESHRAK.BO has a market cap of 113.7M. Regarding current trading prices, MEDPLUS.BO is priced at ₹835.45, while DESHRAK.BO trades at ₹25.65.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
MEDPLUS.BO currently has a P/E ratio of 49.65, whereas DESHRAK.BO's P/E ratio is 30.90. In terms of profitability, MEDPLUS.BO's ROE is +0.12%, compared to DESHRAK.BO's ROE of +0.04%. Regarding short-term risk, MEDPLUS.BO is more volatile compared to DESHRAK.BO. This indicates potentially higher risk in terms of short-term price fluctuations for MEDPLUS.BO.Check DESHRAK.BO's competition here
MEDPLUS.BO vs PARMAX.BO Comparison February 2026
MEDPLUS.BO plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, MEDPLUS.BO stands at 102.8B. In comparison, PARMAX.BO has a market cap of 113.7M. Regarding current trading prices, MEDPLUS.BO is priced at ₹835.45, while PARMAX.BO trades at ₹30.07.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
MEDPLUS.BO currently has a P/E ratio of 49.65, whereas PARMAX.BO's P/E ratio is -3.90. In terms of profitability, MEDPLUS.BO's ROE is +0.12%, compared to PARMAX.BO's ROE of +2.05%. Regarding short-term risk, MEDPLUS.BO is less volatile compared to PARMAX.BO. This indicates potentially lower risk in terms of short-term price fluctuations for MEDPLUS.BO.Check PARMAX.BO's competition here
MEDPLUS.BO vs SHAMROIN.BO Comparison February 2026
MEDPLUS.BO plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, MEDPLUS.BO stands at 102.8B. In comparison, SHAMROIN.BO has a market cap of 110.6M. Regarding current trading prices, MEDPLUS.BO is priced at ₹835.45, while SHAMROIN.BO trades at ₹20.37.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
MEDPLUS.BO currently has a P/E ratio of 49.65, whereas SHAMROIN.BO's P/E ratio is -22.89. In terms of profitability, MEDPLUS.BO's ROE is +0.12%, compared to SHAMROIN.BO's ROE of -0.68%. Regarding short-term risk, MEDPLUS.BO is more volatile compared to SHAMROIN.BO. This indicates potentially higher risk in terms of short-term price fluctuations for MEDPLUS.BO.Check SHAMROIN.BO's competition here
MEDPLUS.BO vs TRINITYLEA.BO Comparison February 2026
MEDPLUS.BO plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, MEDPLUS.BO stands at 102.8B. In comparison, TRINITYLEA.BO has a market cap of 110.4M. Regarding current trading prices, MEDPLUS.BO is priced at ₹835.45, while TRINITYLEA.BO trades at ₹14.24.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
MEDPLUS.BO currently has a P/E ratio of 49.65, whereas TRINITYLEA.BO's P/E ratio is -465.00. In terms of profitability, MEDPLUS.BO's ROE is +0.12%, compared to TRINITYLEA.BO's ROE of -0.01%. Regarding short-term risk, MEDPLUS.BO is less volatile compared to TRINITYLEA.BO. This indicates potentially lower risk in terms of short-term price fluctuations for MEDPLUS.BO.Check TRINITYLEA.BO's competition here
MEDPLUS.BO vs BERLDRG.BO Comparison February 2026
MEDPLUS.BO plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, MEDPLUS.BO stands at 102.8B. In comparison, BERLDRG.BO has a market cap of 106.9M. Regarding current trading prices, MEDPLUS.BO is priced at ₹835.45, while BERLDRG.BO trades at ₹21.60.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
MEDPLUS.BO currently has a P/E ratio of 49.65, whereas BERLDRG.BO's P/E ratio is 702.33. In terms of profitability, MEDPLUS.BO's ROE is +0.12%, compared to BERLDRG.BO's ROE of +0.00%. Regarding short-term risk, MEDPLUS.BO is more volatile compared to BERLDRG.BO. This indicates potentially higher risk in terms of short-term price fluctuations for MEDPLUS.BO.Check BERLDRG.BO's competition here
MEDPLUS.BO vs HINDBIO.BO Comparison February 2026
MEDPLUS.BO plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, MEDPLUS.BO stands at 102.8B. In comparison, HINDBIO.BO has a market cap of 85M. Regarding current trading prices, MEDPLUS.BO is priced at ₹835.45, while HINDBIO.BO trades at ₹8.34.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
MEDPLUS.BO currently has a P/E ratio of 49.65, whereas HINDBIO.BO's P/E ratio is 55.27. In terms of profitability, MEDPLUS.BO's ROE is +0.12%, compared to HINDBIO.BO's ROE of +0.17%. Regarding short-term risk, MEDPLUS.BO is more volatile compared to HINDBIO.BO. This indicates potentially higher risk in terms of short-term price fluctuations for MEDPLUS.BO.Check HINDBIO.BO's competition here
MEDPLUS.BO vs ADLINE.BO Comparison February 2026
MEDPLUS.BO plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, MEDPLUS.BO stands at 102.8B. In comparison, ADLINE.BO has a market cap of 82M. Regarding current trading prices, MEDPLUS.BO is priced at ₹835.45, while ADLINE.BO trades at ₹14.02.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
MEDPLUS.BO currently has a P/E ratio of 49.65, whereas ADLINE.BO's P/E ratio is N/A. In terms of profitability, MEDPLUS.BO's ROE is +0.12%, compared to ADLINE.BO's ROE of N/A. Regarding short-term risk, MEDPLUS.BO is less volatile compared to ADLINE.BO. This indicates potentially lower risk in terms of short-term price fluctuations for MEDPLUS.BO.Check ADLINE.BO's competition here
MEDPLUS.BO vs VIVANZA.BO Comparison February 2026
MEDPLUS.BO plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, MEDPLUS.BO stands at 102.8B. In comparison, VIVANZA.BO has a market cap of 81.6M. Regarding current trading prices, MEDPLUS.BO is priced at ₹835.45, while VIVANZA.BO trades at ₹2.04.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
MEDPLUS.BO currently has a P/E ratio of 49.65, whereas VIVANZA.BO's P/E ratio is -25.50. In terms of profitability, MEDPLUS.BO's ROE is +0.12%, compared to VIVANZA.BO's ROE of -0.03%. Regarding short-term risk, MEDPLUS.BO is more volatile compared to VIVANZA.BO. This indicates potentially higher risk in terms of short-term price fluctuations for MEDPLUS.BO.Check VIVANZA.BO's competition here
MEDPLUS.BO vs EVOQ.BO Comparison February 2026
MEDPLUS.BO plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, MEDPLUS.BO stands at 102.8B. In comparison, EVOQ.BO has a market cap of 80.2M. Regarding current trading prices, MEDPLUS.BO is priced at ₹835.45, while EVOQ.BO trades at ₹3.21.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
MEDPLUS.BO currently has a P/E ratio of 49.65, whereas EVOQ.BO's P/E ratio is 4.54. In terms of profitability, MEDPLUS.BO's ROE is +0.12%, compared to EVOQ.BO's ROE of +0.04%. Regarding short-term risk, MEDPLUS.BO is less volatile compared to EVOQ.BO. This indicates potentially lower risk in terms of short-term price fluctuations for MEDPLUS.BO.Check EVOQ.BO's competition here
MEDPLUS.BO vs DECIPHER.BO Comparison February 2026
MEDPLUS.BO plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, MEDPLUS.BO stands at 102.8B. In comparison, DECIPHER.BO has a market cap of 75.8M. Regarding current trading prices, MEDPLUS.BO is priced at ₹835.45, while DECIPHER.BO trades at ₹7.56.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
MEDPLUS.BO currently has a P/E ratio of 49.65, whereas DECIPHER.BO's P/E ratio is -0.94. In terms of profitability, MEDPLUS.BO's ROE is +0.12%, compared to DECIPHER.BO's ROE of -0.38%. Regarding short-term risk, MEDPLUS.BO is less volatile compared to DECIPHER.BO. This indicates potentially lower risk in terms of short-term price fluctuations for MEDPLUS.BO.Check DECIPHER.BO's competition here
MEDPLUS.BO vs GANGAPHARM.BO Comparison February 2026
MEDPLUS.BO plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, MEDPLUS.BO stands at 102.8B. In comparison, GANGAPHARM.BO has a market cap of 70.9M. Regarding current trading prices, MEDPLUS.BO is priced at ₹835.45, while GANGAPHARM.BO trades at ₹12.00.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
MEDPLUS.BO currently has a P/E ratio of 49.65, whereas GANGAPHARM.BO's P/E ratio is 109.09. In terms of profitability, MEDPLUS.BO's ROE is +0.12%, compared to GANGAPHARM.BO's ROE of +0.01%. Regarding short-term risk, MEDPLUS.BO is more volatile compared to GANGAPHARM.BO. This indicates potentially higher risk in terms of short-term price fluctuations for MEDPLUS.BO.Check GANGAPHARM.BO's competition here
MEDPLUS.BO vs TIAANC.BO Comparison February 2026
MEDPLUS.BO plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, MEDPLUS.BO stands at 102.8B. In comparison, TIAANC.BO has a market cap of 63.2M. Regarding current trading prices, MEDPLUS.BO is priced at ₹835.45, while TIAANC.BO trades at ₹6.45.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
MEDPLUS.BO currently has a P/E ratio of 49.65, whereas TIAANC.BO's P/E ratio is -61.50. In terms of profitability, MEDPLUS.BO's ROE is +0.12%, compared to TIAANC.BO's ROE of -0.01%. Regarding short-term risk, MEDPLUS.BO is less volatile compared to TIAANC.BO. This indicates potentially lower risk in terms of short-term price fluctuations for MEDPLUS.BO.Check TIAANC.BO's competition here
MEDPLUS.BO vs KOBO.BO Comparison February 2026
MEDPLUS.BO plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, MEDPLUS.BO stands at 102.8B. In comparison, KOBO.BO has a market cap of 60M. Regarding current trading prices, MEDPLUS.BO is priced at ₹835.45, while KOBO.BO trades at ₹2.65.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
MEDPLUS.BO currently has a P/E ratio of 49.65, whereas KOBO.BO's P/E ratio is -1.19. In terms of profitability, MEDPLUS.BO's ROE is +0.12%, compared to KOBO.BO's ROE of +0.04%. Regarding short-term risk, MEDPLUS.BO is less volatile compared to KOBO.BO. This indicates potentially lower risk in terms of short-term price fluctuations for MEDPLUS.BO.Check KOBO.BO's competition here
MEDPLUS.BO vs PATIDAR.BO Comparison February 2026
MEDPLUS.BO plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, MEDPLUS.BO stands at 102.8B. In comparison, PATIDAR.BO has a market cap of 52M. Regarding current trading prices, MEDPLUS.BO is priced at ₹835.45, while PATIDAR.BO trades at ₹9.45.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
MEDPLUS.BO currently has a P/E ratio of 49.65, whereas PATIDAR.BO's P/E ratio is -19.29. In terms of profitability, MEDPLUS.BO's ROE is +0.12%, compared to PATIDAR.BO's ROE of -0.04%. Regarding short-term risk, MEDPLUS.BO is more volatile compared to PATIDAR.BO. This indicates potentially higher risk in terms of short-term price fluctuations for MEDPLUS.BO.Check PATIDAR.BO's competition here
MEDPLUS.BO vs WELCURE.BO Comparison February 2026
MEDPLUS.BO plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, MEDPLUS.BO stands at 102.8B. In comparison, WELCURE.BO has a market cap of 37.1M. Regarding current trading prices, MEDPLUS.BO is priced at ₹835.45, while WELCURE.BO trades at ₹0.34.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
MEDPLUS.BO currently has a P/E ratio of 49.65, whereas WELCURE.BO's P/E ratio is 1.14. In terms of profitability, MEDPLUS.BO's ROE is +0.12%, compared to WELCURE.BO's ROE of +0.32%. Regarding short-term risk, MEDPLUS.BO is less volatile compared to WELCURE.BO. This indicates potentially lower risk in terms of short-term price fluctuations for MEDPLUS.BO.Check WELCURE.BO's competition here
MEDPLUS.BO vs TMTIND-B1.BO Comparison February 2026
MEDPLUS.BO plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, MEDPLUS.BO stands at 102.8B. In comparison, TMTIND-B1.BO has a market cap of 34.5M. Regarding current trading prices, MEDPLUS.BO is priced at ₹835.45, while TMTIND-B1.BO trades at ₹6.64.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
MEDPLUS.BO currently has a P/E ratio of 49.65, whereas TMTIND-B1.BO's P/E ratio is -7.83. In terms of profitability, MEDPLUS.BO's ROE is +0.12%, compared to TMTIND-B1.BO's ROE of N/A. Regarding short-term risk, MEDPLUS.BO is more volatile compared to TMTIND-B1.BO. This indicates potentially higher risk in terms of short-term price fluctuations for MEDPLUS.BO.Check TMTIND-B1.BO's competition here
MEDPLUS.BO vs FABINO.BO Comparison February 2026
MEDPLUS.BO plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, MEDPLUS.BO stands at 102.8B. In comparison, FABINO.BO has a market cap of 27.5M. Regarding current trading prices, MEDPLUS.BO is priced at ₹835.45, while FABINO.BO trades at ₹13.10.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
MEDPLUS.BO currently has a P/E ratio of 49.65, whereas FABINO.BO's P/E ratio is -17.95. In terms of profitability, MEDPLUS.BO's ROE is +0.12%, compared to FABINO.BO's ROE of +0.01%. Regarding short-term risk, MEDPLUS.BO is less volatile compared to FABINO.BO. This indicates potentially lower risk in terms of short-term price fluctuations for MEDPLUS.BO.Check FABINO.BO's competition here